Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,628,710
  • Shares Outstanding, K 58,314
  • Annual Sales, $ 36,500 K
  • Annual Income, $ 673,730 K
  • EBIT $ -476 M
  • EBITDA $ -484 M
  • 60-Month Beta 0.91
  • Price/Sales 36.22
  • Price/Cash Flow N/A
  • Price/Book 1.28

Options Overview Details

View History
  • Implied Volatility 74.72% (+5.29%)
  • Historical Volatility 59.41%
  • IV Percentile 82%
  • IV Rank 16.73%
  • IV High 254.54% on 11/18/25
  • IV Low 38.58% on 05/21/25
  • Expected Move (DTE 16) 2.68 (9.67%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,050
  • Volume Avg (30-Day) 564
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 57,016
  • Open Int (30-Day) 66,531
  • Expected Range 25.02 to 30.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.97
  • Number of Estimates 6
  • High Estimate -1.81
  • Low Estimate -2.12
  • Prior Year -1.74
  • Growth Rate Est. (year over year) -13.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.25 +5.52%
on 01/20/26
29.93 -7.45%
on 01/27/26
+0.52 (+1.91%)
since 01/02/26
3-Month
22.24 +24.55%
on 11/19/25
46.00 -39.78%
on 11/18/25
-12.30 (-30.75%)
since 11/04/25
52-Week
22.24 +24.55%
on 11/19/25
46.00 -39.78%
on 11/18/25
-6.31 (-18.55%)
since 02/04/25

Most Recent Stories

More News
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.70 (-0.82%)
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

AQVESMEâ„¢ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter...

AGIO : 27.70 (-0.82%)
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.70 (-0.82%)
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia...

AGIO : 27.70 (-0.82%)
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.70 (-0.82%)
Stocks Settle Higher Before Nvidia Earnings

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.56%. December...

MSTR : 129.09 (-3.13%)
MPC : 195.92 (+4.45%)
GOOGL : 333.04 (-1.96%)
GTLB : 32.54 (-0.91%)
ADI : 320.44 (+2.94%)
COIN : 168.62 (-6.14%)
OXY : 46.69 (+3.16%)
DY : 363.20 (-7.28%)
^BTCUSD : 72,834.96 (+0.29%)
SPY : 686.19 (-0.48%)
QS : 8.49 (-4.18%)
MP : 60.55 (-6.28%)
Stocks Supported by Strength in Megacap Tech and Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.74%. December E-mini S&P...

AMAT : 297.60 (-6.61%)
MPC : 195.92 (+4.45%)
GOOGL : 333.04 (-1.96%)
GTLB : 32.54 (-0.91%)
AVGO : 308.05 (-3.83%)
CVX : 181.23 (+1.79%)
IRM : 90.07 (+1.65%)
ADI : 320.44 (+2.94%)
$IUXX : 24,891.24 (-1.77%)
ASML : 1,339.13 (-4.07%)
ZNH26 : 111-200 (+0.01%)
OXY : 46.69 (+3.16%)
Stock Indexes Gain on Strength in Alphabet and Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.60%. December E-mini S&P futures...

AMAT : 297.60 (-6.61%)
MPC : 195.92 (+4.45%)
GOOGL : 333.04 (-1.96%)
GTLB : 32.54 (-0.91%)
CVX : 181.23 (+1.79%)
$IUXX : 24,891.24 (-1.77%)
ASML : 1,339.13 (-4.07%)
ZNH26 : 111-200 (+0.01%)
OXY : 46.69 (+3.16%)
AGIO : 27.70 (-0.82%)
ESH26 : 6,928.50 (+0.32%)
FANG : 168.99 (+3.75%)
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did...

AGIO : 27.70 (-0.82%)
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.70 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 28.72
2nd Resistance Point 28.45
1st Resistance Point 28.08
Last Price 27.70
1st Support Level 27.44
2nd Support Level 27.17
3rd Support Level 26.80

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
Last Price 27.70
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar